GlassScriptPhysician profile
Michael R Mills
NPI 1811948359
$8,081.08
in general payments reported to CMS, 2019-2025
46 companies · $2,116 in 2025
The $2,116 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $270 · 2021: $728 · 2022: $892 · 2023: $1,276 · 2024: $2,000 · 2025: $2,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,289 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,289.43 |
| Education | $103.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,123.32 | 2019-2025 | |
| Janssen Biotech, INC. | $785.94 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $737.41 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $544.26 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $464.72 | 2019-2025 | |
| Pfizer INC. | $334.41 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $241.71 | 2024-2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.16 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Ardelyx, INC. | $193.71 | 2023-2025 | Ibsrela |
| Endogastric Solutions, INC | $191.82 | 2019-2020 | |
| Celgene Corporation | $182.83 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $174.00 | 2019-2024 | Ocaliva |
| Fujifilm Healthcare Americas Corporation | $169.69 | 2024 | Fujifilm |
| Lilly USA, LLC | $167.74 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $143.82 | 2019-2024 | Dificid |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $129.37 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $116.58 | 2024-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $104.66 | 2019-2025 | Rebyota |
| Qol Medical, LLC | $93.65 | 2021-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $92.79 | 2021-2023 | |
| Madrigal Pharmaceuticals | $81.19 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $71.94 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Aimmune Therapeutics, INC. | $62.31 | 2025 | Zenpep |
| Ucb, INC. | $61.20 | 2019 | |
| Capsovision, INC. | $44.43 | 2023-2024 | Capsocam Plus |
| Organon LLC | $43.89 | 2022 | |
| Braintree Laboratories, INC. | $42.28 | 2022-2025 | Suflave, Sutab |
| Perspectum Diagnostics LTD | $39.92 | 2022 | |
| Evoke Pharma, INC. | $27.56 | 2025 | |
| Shire North American Group INC | $27.54 | 2019 | |
| Exact Sciences Corporation | $25.13 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $24.80 | 2019 | |
| Davol INC. | $24.08 | 2024 | Phasix Mesh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.93 | 2023 | Cyltezo |
| Amgen INC. | $22.28 | 2021 | |
| Shionogi INC | $22.19 | 2019 | |
| Novo Nordisk INC | $20.85 | 2025 | Wegovy |
| Intra-Sana Laboratories | $20.82 | 2022-2023 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Napo Pharmaceuticals INC | $17.80 | 2025 | Mytesi |
| Medtronic, INC. | $15.50 | 2021 | |
| Lucid Diagnostics INC. | $14.96 | 2022 | |
| Celltrion USA INC. | $14.68 | 2025 | Vegzelma |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 | |
| Echosens North America, INC. | $9.13 | 2025 | Fibroscan |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.